Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) shot up 0.7% on Tuesday . The company traded as high as $251.72 and last traded at $251.72. 53 shares were traded during mid-day trading, an increase of 107% from the average session volume of 26 shares. The stock had previously closed at $250.08.
Bio-Rad Laboratories Stock Performance
The stock has a market cap of $6.85 billion, a PE ratio of -3.30 and a beta of 0.81. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average price of $246.75 and a 200 day moving average price of $277.14.
Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.54 earnings per share for the quarter. Bio-Rad Laboratories had a positive return on equity of 4.32% and a negative net margin of 85.16%. The company had revenue of $585.40 million for the quarter.
About Bio-Rad Laboratories
(
Get Free Report)
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Featured Stories
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
